Advice
following an abbreviated submission:
pegaspargase (Oncaspar®) is accepted for use within NHS Scotland.
Indication under review: as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
Pegaspargase (Oncaspar®) has been used in NHS Scotland as an unlicensed medicine for the treatment of ALL in children and adults; it has now been granted a product license.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- pegaspargase (Oncaspar)
- SMC ID:
- 1197/16
- Indication:
- As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
- Pharmaceutical company
- Baxalta
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 November 2016